Peter S. Hammerman
Harvard University · 677 works · 40,266 citations · h-index 73
Top works
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- Comprehensive molecular profiling of lung adenocarcinoma
- Comprehensive genomic characterization of squamous cell lung cancers
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- Non-small-cell lung cancers: a heterogeneous set of diseases
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival
- Fuel feeds function: energy metabolism and the T-cell response
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma